Chapter 22 Future directions - photosensitizer targeting and new disease indications

Comprehensive Series in Photosciences

Volumn 2, Issue C, 2001, Pages 339-366

  Hamblin, Michael R ^a   Ortel, Bernhard ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957065756     PISSN: 1568461X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1568-461X(01)80126-5     Document Type: Article

References (166)

1. Hansen L.A., Sigman C.C., Andreola F., Ross S.A., Kelloff G.J., and De Luca L.M. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 21 (2000) 1271-1279
2. Randolph T.R. Acute promyelocytic leukemia (AML-M3) - Part 1: Pathophysiology, clinical diagnosis, and differentiation therapy. Clin. Lab. Sci. 13 (2000) 98-105
3. Petersen O.W., Ronnov-Jessen L., Weaver V.M., and Bissell M.J. Differentiation and cancer in the mammary gland: shedding light on an old dichotomy. Adv. Cancer Res. 75 (1998) 135-161
4. Ortel B., Chen N., Brissette J., Dotto G.P., Maytin E., and Hasan T. Differentiation-specific increase in ALA-induced protoporphyrin IX accumulation in primary mouse keratinocytes. Br. J. Cancer 77 (1998) 1744-1751
5. Lipson R.L., and Baldes E.J. The photodynamic, properties of a particular hematoporphyrin derivative. Arch. Dermatol. 82 (1960) 508
6. Boyle R.W., and Dolphin D. Structure and biodistribution relationship of photodynamic sensitizers. Photochem. Photobiol. 64 (1996) 469-485
7. Hamblin M.R., and Newman E.L. On the mechanism of the tumour-localising effect in photodynamic therapy. J. Photochem. Photobiol. B 23 (1994) 3-8
8. Jori G., and Reddi E. The role of lipoproteins in the delivery of tumour-targeting photosensitizers. Int. J. Biochem. 25 (1993) 1369-1375
9. Maziere J.C., Santus R., Morliere P., Reyftmann J.P., Candide C., Mora L., Salmon S., Maziere C., Gatt S., and Dubertret L. Cellular uptake and photosensitizing properties of anticancer porphyrins in cell membranes and low and high density lipoproteins. J. Photochem. Photobiol. B 6 (1990) 61-68
10. Kessel D., Morgan A., and Garbo G.M. Sites and efficacy of photodamage by tin etiopurpurin in vitro using different delivery systems. Photochem. Photobiol. 54 (1991) 193-196
11. Kongshaug M., Moan J., and Brown S.B. The distribution of porphyrins with different tumour localising ability among human plasma proteins. Br. J. Cancer 59 (1989) 184-188
12. Korbelik M. Low density lipoprotein receptor pathway in the delivery of Photofrin: how much is it relevant for selective accumulation of the photosensitizer in tumors?. J. Photochem. Photobiol. B 12 (1992) 107-109
13. Yuan F., Leunig M., Berk D.A., and Jain R.K. Microvascular permeability of albumin, vascular surface area, and vascular volume measured in human adenocarcinoma LS 174T using dorsal chamber in SCID mice. Microvasc. Res. 45 (1993) 269-289
14. [published erratum appears in: Br. J. Cancer, Jan. 1995, 71(1), 214.]. Allison B.A., Pritchard P.H., and Levy J.G. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. Br. J. Cancer 69 (1994) 833-839
15. Roberts W.G., and Hasan T. Role of neovasculature and vascular permeability on the tumor retention of photodynamic agents. Cancer Res. 52 (1992) 924-930
16. Korbelik M., and Krosl G. Photofrin accumulation in malignant and host cell populations of a murine fibrosarcoma. Photochem. Photobiol. 62 (1995) 162-168
17. Korbelik M., Krosl G., and Chaplin D.J. Photofrin uptake by murine macrophages. Cancer Res. 51 (1991) 2251-2255
18. Pottier R., and Kennedy J.C. The possible role of ionic species in selective biodistribution of photochemotherapeutic agents toward neoplastic tissue. J. Photochem. Photobiol. B 8 (1990) 1-16
19. Reddi E. Role of delivery vehicles for photosensitizers in the photodynamic therapy of tumours. J. Photochem. Photobiol. B 37 (1997) 189-195
20. Woodburn K., Sykes E., and Kessel D. Interactions of Solutol HS 15 and Cremophor EL with plasma lipoproteins. Int. J. Biochem. Cell Biol. 27 (1995) 693-699
21. Woodburn K., Chang C.K., Lee S., Henderson B., and Kessel D. Biodistribution and PDT efficacy of a ketochlorin photosensitizer as a function of the delivery vehicle. Photochem. Photobiol. 60 (1994) 154-159
22. Ginevra F., Biffanti S., Pagnan A., Biolo R., Reddi E., and Jori G. Delivery of the tumour, photosensitizer zinc(II)-phthalocyanine to serum proteins by different liposomes: studies in vitro and in vivo. Cancer Lett. 49 (1990) 59-65
23. Jiang F., Lilge L., Logie B., Li Y., and Chopp M. Photodynamic therapy of 9L gliosarcoma with liposome-delivered photofrin. Photochem. Photobiol. 65 (1997) 701-706
24. Richter A.M., Waterfield E., Jain A.K., Canaan A.J., Allison B.A., and Levy J.G. Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model. Photochem. Photobiol. 57 (1993) 1000-1006
25. Polo L., Segalla A., Jori G., Bocchiotti G., Verna G., Franceschini R., Mosca R., and De Filippi P.G. Liposome-delivered 131I-labelled Zn(II)-phthalocyanine as a radiodiagnostic agent for tumours. Cancer Lett. 109 (1996) 57-61
26. Allemann E., Rousseau J., Brasseur N., Kudrevich S.V., Lewis K., and van Lier J.E. Photodynamic therapy of tumours with hexadecafluoro zinc phthalocyanine formulated in PEG-coated poly(lactic acid) nanoparticles. Int. J. Cancer 66 (1996) 821-824
27. Margalit R., and Silbiger E. Albumin microspheres as delivery systems for photodynamic drugs: physico-chemical studies and their implications for in vivo situations. J. Microencapsul. 2 (1985) 183-196
28. Schmidt-Erfurth U., Bauman W., Gragoudas E., Flotte T.J., Michaud N.A., Birngruber R., and Hasan T. Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin. Ophthalmology 101 (1994) 89-99
29. Larroque C., Pelegrin A., and Van Lier J.E. Serum albumin as a vehicle for zinc phthalocyanine: photodynamic activities in solid tumour models. Br. J. Cancer 74 (1996) 1886-1890
30. Duncan R., and Spreafico F. Polymer conjugates. Pharmacokinetic considerations for design and development. Clin. Pharmacokinet. 27 (1994) 290-306
31. Soukos N.S., Hamblin M.R., and Hasan T. The effect of charge on cellular uptake and phototoxicity of polylysine chlorin e6-conjugates. Photochem. Photobiol. 65 (1997) 723-729
32. Goff B.A., Bamberg M., and Hasan T. Photoimmunotherapy of human ovarian carcinoma cells ex vivo. Cancer Res. 51 (1991) 4762-4767
33. Krinick N.L., Sun Y., Joyner D., Spikes J.D., Straight R.C., and Kopecek J. A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light. J. Biomater. Sci. Polym. Ed. 5 (1994) 303-324
34. Davis N., Liu D., Jain A.K., Jiang S.Y., Jiang F., Richter A., and Levy J.G. Modified polyvinyl alcohol-benzoporphyrin derivative conjugates as phototoxic agents. Photochem. Photobiol. 57 (1993) 641-647
35. Hamblin M.R., Rajadhyaksha M., Momma T., Soukos N.S., and Hasan T. In vivo fluorescence imaging of the transport of charged chlorin e6 conjugates in a rat orthotopic prostate tumours. Br. J. Cancer. 81 (1999) 261-268
36. Ris H.B., Im Hof V., Stewart C.M., Mettler D., and Altermatt H.J. Endobronchial photodynamic therapy: comparison of mTHPC and polyethylene glycol-derived mTHPC on human tumor xenografts and tumor-free bronchi of minipigs. Lasers Surg. Med. 23 (1998) 25-32
37. Ris H.B., Krueger T., Giger A., Lim C.K., Stewart J.C., Althaus U., and Altermatt H.J. Photodynamic therapy with mTHPC and polyethylene glycol-derived mTHPC: a comparative study on human tumour xenografts. Br. J. Cancer 79 (1999) 1061-1066
38. Brasseur N., Ouellet R., Madeleine C.L., and van Lier J.E. Water-soluble aluminium phthalocyanine-polymer conjugates for PDT: photodynamic activities and pharmacokinetics in tumour-bearing mice. Br. J. Cancer 80 (1999) 1533-1541
39. Bachor R., Shea C.R., Gillies R., and Hasan T. Photosensitized destruction of human bladder carcinoma cells treated with chlorin e6-conjugated microspheres. Proc. Natl. Acad. Sci. USA 88 (1991) 1580-1584
40. Vrouenraets M.B., Visser G.W., Stewart F.A., Stigter M., Oppelaar H., Postmus P.E., Snow G.B., and van Dongen G.A. Development of meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for photoimmunotherapy. Cancer Res. 59 (1999) 1505-1513
41. Oseroff A.R., Ohuoha D., Hasan T., Bommer J.C., and Yarmush M.L. Antibodytargeted photolysis: selective photodestruction of human T-cell leukemia cells using monoclonal antibody-chlorin e6 conjugates. Proc. Natl. Acad. Sci. USA 83 (1986) 8744-8748
42. Hasan T., Lin A., Yarmush D., Oseroff A., and Yarmush M. Monoclonal antibody-chromophore conjugates as selective photoxins. J. Controlled Release 10 (1989) 107-117
43. Jiang F.N., Jiang S., Liu D., Richter A., and Levy J.G. Development of technology for linking photosensitizers to a model monoclonal antibody. J. Immunol. Methods 134 (1990) 139-149
44. Omelyanenko V., Kopeckova P., Gentry C., Shiah J.G., and Kopecek J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. J. Drug Target 3 (1996) 357-373
45. Hamblin M.R., Miller J.L., and Hasan T. Effect of charge on the interaction of site-specific photoimmunoconjugates with human ovarian cancer cells. Cancer Res. 56 (1996) 5205-5210
46. Mew D., Wat C.K., Towers G.H., and Levy J.G. Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. J. Immunol. 130 (1983) 1473-1477
47. Steele J.K., Liu D., Stammers A.T., Whitney S., and Levy J.G. Suppressor deletion therapy: selective elimination of T suppressor cells in vivo using a hematoporphyrin conjugated monoclonal antibody permits animals to reject syngeneic tumor cells. Cancer Immunol. Immunother. 26 (1988) 125-131
48. Goff B.A., Hermanto U., Rumbaugh J., Blake J., Bamberg M., and Hasan T. Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model. Br. J. Cancer 70 (1994) 474-480
49. Goff B.A., Blake J., Bamberg M.P., and Hasan T. Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model. Br. J. Cancer. 74 (1996) 1194-1198
50. Molpus K.L., Hamblin M.R., Rizvi I., and Hasan T. Intraperitoneal photoimmunotherapy of ovarian carcinoma xenografts in nude mice using charged photoimmunoconjugates. Gynecol. Oncol. 76 (2000) 397-404
51. Duska L.R., Hamblin M.R., Bamberg M.P., and Hasan T. Biodistribution of charged F(ab')2 photoimmunoconjugates in a xenograft model of ovarian cancer. Br. J. Cancer. 75 (1997) 837-844
52. Lilge L., Molpus K., Hasan T., and Wilson B.C. Light dosimetry for intraperitoneal photodynamic therapy in a murine xenograft model of human epithelial ovarian carcinoma. Photochem. Photobiol. 68 (1998) 281-288
53. Schmidt S., Wagner U., Oehr P., and Krebs D. Clinical use of photodynamic therapy in gynecologic tumor patients - antitody-targeted photodynamic laser therapy as a new oncologic treatment procedure. Zentralbl. Gynakol. 114 (1992) 307-311
54. Schmidt S., Wagner U., Schultes B., Oehr P., Decleer W., Ertmer W., Lubaschowski H., Biersack H.J., and Krebs D. Photodynamic laser therapy with antibody-bound dyes. A new procedure in therapy of gynecologic malignancies. Fortschr. Med. 110 (1992) 298-301
55. Duska L.R., Hamblin M.R., Miller J.L., and Hasan T. Combination photo-immunotherapy and cisplatin: effects on human ovarian cancer ex vivo. J. Natl. Cancer Inst. 91 (1999) 1557-1563
56. Schmidt-Erfurth U., Diddens H., Birngruber R., and Hasan T. Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates. Br. J. Cancer 75 (1997) 54-61
57. Hamblin M.R., and Newman E.L. Photosensitizer targeting in photodynamic therapy. II. Conjugates of haematoporphyrin with serum lipoproteins. J. Photochem. Photobiol. B 26 (1994) 147-157
58. Hamblin M.R., and Newman E.L. Photosensitizer targeting in photodynamic therapy. I. Conjugates of haematoporphyrin with albumin and transferrin. J. Photochem. Photobiol. B 26 (1994) 45-56
59. Gijsen A., and De Witte P. Photocytotoxic action of EGF-PVA-Sn(IV) chlorin e6 and EGF-dextran-Sn(IV)chlorin e6 internalizable conjugates on A431 cells. Int. J. Oncol. 13 (1998) 1171-1177
60. Akhlynina T.V., Rosenkranz A.A., Jans D.A., and Sobolev A.S. Insulin-mediated intracellular targeting enhances the photodynamic activity of chlorin (e6). Cancer Res. 55 (1995) 1014-1019
61. Akhlynina T.V., Jans D.A., Rosenkranz A.A., Statsyuk N.V., Balashova I.Y., Toth G., Pavo I., Rubin A.B., and Sobolev A.S. Nuclear targeting of chlorin (e6) enhances its photosensitizing activity. J. Biol. Chem. 272 (1997) 20328-20331
62. Rhodes L.E., Tsoukas M.M., Anderson R.R., and Kollias N. Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin. J. Invest. Dermatol. 108 (1997) 87-91
63. Lee S., McAuliffe D.J., Flotte T.J., Kollias N., and Doukas A.G. Photomechanical transcutaneous delivery of macromolecules. J. Invest Dermatol. 111 (1998) 925-929
64. Lee S., Kollias N., McAuliffe D.J., Flotte T.J., and Doukas A.G. Topical drug delivery in humans with a single photomechanical wave. Pharm. Res. 16 (1999) 1717-1721
65. Vanbever R., and Preat V. In vivo efficacy and safety of skin electroporation. Adv. Drug Deliv. Rev. 35 (1999) 77-88
66. Mitragotri S., and Kost J. Low-frequency sonophoresis: a noninvasive method of drug delivery and diagnostics. Biotechnol. Prog. 16 (2000) 488-492
67. Beyer W. Systems for light application and dosimetry in photodynamic therapy. J. Photochem. Photobiol. B 36 (1996) 153-156
68. Lilge L., Pomerleau N., McIlroy B., and Vesselov L. Multi-tasking optical fiber probes for fluence-rate and fluorescent drug monitoring in vivo. Proc. Soc. Photo-Opt. Instr. Eng. 3909 (2000) 66-75
69. Madsen S.J., Anderson E.R., Haskell R.C., and Tromberg B.J. Protable, highbandwidth frequency-domain photon migration instrument for tissue spectroscopy. Opt. Lett. 19 (1994) 1934-1936
70. Pogue B.W., Lilge L., Patterson M.S., Wilson B.C., and Hasan T. The absorbed photodynamic dose examined from pulsed and cw light using tissue-simulating dosimeters. Applied Optics. 36 (1997) 7257-7269
71. Pogue B.W., and Burke G.C. Fiber optic bundle design for quantitative fluorescence measurement from tissue. Appl. Opt. 37 (1998) 7429-7436
72. Pogue B.W., McBride T., Osterberg U., and Paulsen K. Comparison of imaging geometries for diffuse optical tomography of tissue. Opt. Exp. 4 (1999) 270-286
73. McCaughan Jr. J.S., Guy J.T., Hicks W., Laufman L., Nims T.A., and Walker J. Photodynamic therapy for cutaneous and subcutaneous malignant neoplasms. Arch. Surg. 124 (1989) 211-216
74. Renschler M.F., Yuen A.R., Panella T.J., Wieman T.J., Dougherty S., Esserman L., Panjehpour M., Taber S.W., Fingar V.H., Lowe E., Engel J.S., Lum B., Woodburn K.W., Cheong W., and Miller R.A. Photodynamic therapy trials with lutetium texaphyrin (Lu-Tex) in patients with locally recurrent breast cancer. Proc. SPIE. 3247 (1998) 35-39
75. Busetti A., Soncin M., Jori G., and Rodgers M.A. High efficiency of benzoporphyrin derivative in the photodynamic therapy of pigmented malignant melanoma. Br. J. Cancer 79 (1999) 821-824
76. Michailov N., Peeva M., Angelov I., Wohrle D., Muller S., Jori G., Ricchelli F., and Shopova M. Fluence rate effects on photodynamic therapy of B16 pigmented melanoma. J Photochem. Photobiol. B 37 (1997) 154-157
77. Young L.H., Howard M.A., Hu L.K., Kim R.Y., and Gragoudas E.S. Photodynamic therapy of pigmented choroidal melanomas using a liposomal preparation of benzoporphyrin derivative. Arch. Ophthalmol. 114 (1996) 186-192
78. Biolo R., Jori G., Soncin M., Rihter B., Kenney M.E., and Rodgers M.A. Effect of photosensitizer delivery system and irradiation parameters on the efficiency of photodynamic therapy of B16 pigmented melanoma in mice. Photochem. Photobiol. 63 (1996) 224-228
79. Woodburn K.W., Fan Q., Kessel D., Luo Y., and Young S.W. Photodynamic therapy of B16F10 murine melanoma with lutetium texaphyrin. J. Invest Dermatol. 110 (1998) 746-751
80. Busetti A., Soncin M., Jori G., Kenney M.E., and Rodgers M.A. Treatment of malignant melanoma by high-peak-power 1064 nm irradiation followed by photodynamic therapy. Photochem. Photobiol. 68 (1998) 377-381
81. Busetti A., Soncin M., Reddi E., Rodgers M.A., Kenney M.E., and Jori G. Photothermal sensitization of amelanotic melanoma cells by Ni(II)-octabutoxy-naphthalocyanine. J. Photochem. Photobiol. B 53 (1999) 103-109
82. Hebeda K.M., Huizing M.T., Brouwer P.A., van der Meulen F.W., Hulsebosch H.J., Reiss P., Oosting J., Veenhof C.H., and Bakker P.J. Photodynamic therapy in AIDS-related cutaneous Kaposi's sarcoma. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10 (1995) 61-70
83. Bernstein Z.P., Wilson B.D., Oseroff A.R., Jones C.M., Dozier S.E., Brooks J.S., Cheney R., Foulke L., Mang T.S., Bellnier D.A., and Dougherty T.J. Photofrin photodynamic therapy for treatment of AIDS-related cutaneous Kaposi's sarcoma. Aids 13 (1999) 1697-1704
84. Jones J.L., Hanson D.L., Dworkin M.S., and Jaffe H.W. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 24 (2000) 270-274
85. Bower M., Fox P., Fife K., Gill J., Nelson M., and Gazzard B. Highly active antiretroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. Aids 13 (1999) 2105-2111
86. Cattelan A.M., Calabro M.L., Aversa S.M., Zanchetta M., Meneghetti F., De Rossi A., and Chieco-Bianchi L. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur. J. Cancer 35 (1999) 1809-1815
87. Korbelik M. Induction of tumor immunity by photodynamic therapy. J. Clin. Laser. Med. Surg. 14 (1996) 329-334
88. Korbelik M., and Dougherty G.J. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res. 59 (1999) 1941-1946
89. Anderson R.R., and Parrish J.A. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 220 (1983) 524-527
90. Polla L.L., Jacques S.L., Margolis R.J., Prince M.R., Anderson R.R., Parrish J.A., and Tan O.T. Selective photothermolysis: contribution to the treatment of flat angiomas (port wine stains) by laser. Ann. Dermatol. Venereol. 114 (1987) 497-505
91. Schmidt-Erfurth U., Miller J.W., Sickenberg M., Laqua H., Barbazetto I., Gragoudas E.S., Zografos L., Piguet B., Pournaras C.J., Donati G., Lane A.M., Birngruber R., van den Berg H., Strong H.A., Manjuris U., Gray T., Fsadni M., and Bressler N.M. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch. Ophthalmol. 117 (1999) 1177-1187
92. Barbazetto I., and Schmidt-Erfurth U. Photodynamic therapy of choroidal hemangioma: two case reports. Graefes Arch. Clin. Exp. Ophthalmol. 238 (2000) 214-221
93. Young S.W., Woodburn K.W., Wright M., Mody T.D., Fan Q., Sessler J.L., Dow W.C., and Miller R.A. Lutetium texaphyrin (PCI-0123): a near-infrared, water-soluble photosensitizer. Photochem. Photobiol. 63 (1996) 892-897
94. Kostenich G., Orenstein A., Roitman L., Malik Z., and Ehrenberg B. In vivo photodynamic therapy with the new near-IR absorbing water soluble photosensitizer lutetium texaphyrin and a high intensity pulsed light delivery system. J. Photochem. Photobiol. B 39 (1997) 36-42
95. Krueger J.G., Walters I.B., Miyazawa M., Gilleaudeau P., Hakimi J., Light S., Sherr A., and Gottlieb A.B. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J. Am. Acad. Dermatol. 43 (2000) 448-458
96. Gottlieb A., Krueger J.G., Bright R., Ling M., Lebwohl M., Kang S., Feldman S., Spellman M., Wittkowski K., Ochs H.D., Jardieu P., Bauer R., White M., Dedrick R., and Garovoy M. Effects of administration of a single dose of a humanized monoclonal antibody to CD1 1a on the immunobiology and clinical activity of psoriasis. J. Am. Acad. Dermatol. 42 (2000) 428-435
97. Abrams J.R., Kelley S.L., Hayes E., Kikuchi T., Brown M.J., Kang S., Lebwohl M.G., Guzzo C.A., Jegasothy B.V., Linsley P.S., and Krueger J.G. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J. Exp. Med. 192 (2000) 681-694
98. Krueger J.G., Wolfe J.T., Nabeya R.T., Vallat V.P., Gilleaudeau P., Heftler N.S., Austin L.M., and Gottlieb A.B. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J. Exp. Med. 182 (1995) 2057-2068
99. Coven T.R., Walters I.B., Cardinale I., and Krueger J.G. PUVA-induced lymphocyte apoptosis: mechanism of action in psoriasis. Photodermatol. Photoimmunol. Photomed. 15 (1999) 22-27
100. Murphy F.P., Coven T.R., Burack L.H., Gilleaudeau P., Cardinale I., Auerbach R., and Krueger J.G. Clinical clearing of psoriasis by 6-thioguanine correlates with cutaneous T-cell depletion via apoptosis: evidence for selective effects on activated T lymphocytes. Arch. Dermatol. 135 (1999) 1495-1502
101. Vallat V.P., Gilleaudeau P., Battat L., Wolfe J., Nabeya R., Heftler N., Hodak E., Gottlieb A.B., and Krueger J.G. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J. Exp. Med. 180 (1994) 283-296
102. Rosenberg C.S. Wound healing in the patient with diabetes mellitus. Nurs. Clin. North Am. 25 (1990) 247-261
103. Kamler M., Lehr H.A., Saetzler R.K., Galla T.J., and Messmer K. Impact of ischemia on tissue oxygenation and wound healing: improvement by vasoactive medication. Adv. Exp. Med. Biol. 316 (1992) 419-424
104. Dillin L., and Slabaugh P. Delayed wound healing, infection, and nonunion following open reduction and internal fixation of tibial plafond fractures. J. Trauma 26 (1986) 1116-1119
105. Casey J., Flinn W.R., Yao J.S., Fahey V., Pawlowski J., and Bergan J.J. Correlation of immune and nutritional status with wound complications in patients undergoing vascular operations. Surgery 93 (1983) 822-827
106. Reed M.J. Wound repair in older patients: preventing problems and managing the healing. Geriatrics 53 (1998) 88-94
107. Koren H., Alth G., schenk G.M., and Jindra R.H. Photodynamic therapy-an alternative pathway in the treatment of recurrent breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 28 (1994) 463-466
108. Obochi M.O., Canaan A.J., Jain A.K., Richter A.M., and Levy J.G. Targeting activated lymphocytes with photodynamic therapy: susceptibility of mitogen-stimulated splenic lymphocytes to benzoporphyrin derivative (BPD) photosensitization. Photochem. Photobiol. 62 (1995) 169-175
109. Yamamoto N., Sery T.W., Hoober J.K., Willett N.P., and Lindsay D.D. Effectiveness of photofrin II in activation of macrophages and in vitro killing of retinoblastoma cells. Photochem. Photobiol. 60 (1994) 160-164
110. Yamamoto N., Homma S., Nakagawa Y., Hayami M., Imanaga H., Kurimoto M., Mitsuhashi M., and Kimoto T. Activation of mouse macrophages by in vivo and in vitro treatment with a cyanine dye, lumin. J. Photochem. Photobiol. B 13 (1992) 295-306
111. Yamamoto N., Hoober J.K., Yamamoto N., and Yamamoto S. Tumoricidal capacities of macrophages photodynamically activated with hematoporphyrin derivative. Photochem. Photobiol. 56 (1992) 245-250
112. Evans S., Matthews W., Perry R., Fraker D., Norton J., and Pass H.I. Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. J. Natl. Cancer Inst. 82 (1990) 34-39
113. USA Patent Number 5,913,884. Trauner K.B., Hasan T., and Hamblin M.R. Inhibition of fibrosis by photodynamic therapy (1999)
114. Reiken S.R., Wolfort S.F., Berthaume F., Compton C., Tompkins R.G., and Yarmush M.L. Control of hypertrophic scar growth using selective photothermolysis. Lasers Surg. Med. 21 (1997) 7-12
115. Obochi M., Tao J.-S., Hunt D., and Levy J. Photodynamic therapy as a biological modifier. SPIE Proc. 2675 (1996) 122-131
116. USA Patent Number 6,107,466. Hasan T., Hamblin M.R., and Trauner K.B. Acceleration of wound healing by photodynamic therapy (2000)
117. Bennett N., and Schultz G. Growth factors and wound healing: biochemical properties of growth factors and their receptors. Am. J. Surg. 165 (1993) 728-737
118. Frank S., Hubner G., Breier G., Longaker M.T., Greenhalgh D.G., and Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J. Biol. Chem. 270 (1995) 12607-12613
119. Puolakkainen P.A., Twardzik D.R., Ranchalis J.E., Pankey S.C., Reed M.J., and Gombotz W.R. The enhancement in wound healing by transforming growth factor-beta 1 (TGF-beta 1) depends on the topical delivery system. J. Surg. Res. 58 (1995) 321-329
120. Brown R.L., Breeden M.P., and Greenhalgh D.G. PDGF and TGF-alpha act synergistically to improve wound healing in the genetically diabetic mouse. J. Surg. Res. 56 (1994) 562-570
121. Brown G.L., Curtsinger L.J., White M., Mitchell R.O., Pietsch J., Nordquist R., von Fraunhofer A., and Schultz G.S. Acceleration of tensile strength of incisions treated with EGF and TGF-beta. Ann. Surg. 208 (1988) 788-794
122. Fukunaga K., Hijikata S., Ishimura K., Sonoda R., Irie T., and Uekama K. Aluminium beta-cyclodextrin sulphate as a stabilizer and sustained-release carrier for basic fibroblast growth factor. J. Pharm. Pharmacol. 46 (1994) 168-171
123. Davies M.J., Mitchell C.A., Maley M.A., Grounds M.D., Harvey A.R., Plant G.W., Wood D.J., Hong Y., and Chirila T.V. In vitro assessment of the biological activity of basic fibroblast growth factor released from various polymers and biomatrices. J. Biomater. Appl. 12 (1997) 31-56
124. Nicoll S.B., Radin S., Santos E.M., Tuan R.S., and Ducheyne P. In vitro release kinetics of biologically active transforming growth factor-beta 1 from a novel porous glass carrier. Biomaterials 18 (1997) 853-859
125. abstract. Hasan T., and Hamblin M.R. Light mediated modulation of wound healing. Proceedings of the Twentieth Biennial Cornea Research Conference. Boston, MA (1997) 34
126. Bartholomew R.S., Clarke M., and Phillips C.I. "Dye/light" Dye-induced photosensitization of herpes virus. A clinical trial on humans. Trans. Ophthalmol. Soc. U.K. 97 (1977) 508-509
127. Kaufman R.H., Gardner H.L., Brown D., Wallis C., Rawls W.E., and Melnick J.L. Herpes genitalis treated by photodynamic inactivation of virus. Am. J. Obstet. Gynecol. 117 (1973) 1144-1146
128. Friedrich Jr. E.G., Kaufman R.H., Lynch P.J., and Woodruff D. Vulvar histology after neutral red photoinactivation of herpes simplex virus. Obstet. Gynecol. 48 (1976) 564-570
129. Moore C., Wallis C., Melnick J.L., and Kuns M.D. Photodynamic treatment of herpes keratitis. Infect Immun. 5 (1972) 169-171
130. Myers M.G., Oxman M.N., Clark J.E., and Arndt K.A. Failure of neutral-red photodynamic inactivation in recurrent herpes simplex virus infections. N. Engl. J. Med. 293 (1975) 945-949
131. Kucera L.S., and Gusdon J.P. Transformation of human embryonic fibroblasts by photodynamically inactivated herpes simplex virus, type 2 at supra-optimal temperature. J. Gen. Virol. 30 (1976) 257-261
132. Berthiaume F., Reiken S., Toner M., Tompkins R., and Yarmush M. Antibody-targeted photolysis of bacteria in vivo. Biotechnology 12 (1994) 703-706
133. Vaara M. Agents that increase the permeability of the outer membrane. MicroBiol. Rev. 56 (1992) 395-411
134. Hancock R.E. The bacterial outer membrane as a drug barrier. Trends Microbiol. 5 (1997) 37-42
135. Merchat M., Bertolini G., Giacomini P., Villanueva A., and Jori G. Meso-substituted cationic porphyrins as efficient photosensitizers of gram-positive and gram-negative bacteria. J. Photochem. Photobiol. B 32 (1996) 153-157
136. Nitzan Y., Gutterman M., Malik Z., and Ehrenberg B. Inactivation of gram-negative bacteria by photosensitized porphyrins. Photochem. Photobiol. 55 (1992) 89-96
137. Bertoloni G., Rossi F., Valduga G., Jori G., and van Lier J. Photosensitizing activity of water- and lipid-soluble phthalocyanines on Escherichia coli. FEMS Microbiol. Lett. 59 (1990) 149-155
138. Eltringham I. Mupirocin resistance and methicillin-resistant Staphylococcus aureus (MRSA). J. Hosp. Infect. 35 (1997) 1-8
139. Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am. J. Med. 104 (1998) 29
140. Holder I.A., and Neely A.N. Fear of MRSA-potential for future disaster. Burns 24 (1998) 99-103
141. Fekety R. The management of the carrier of methicillin-resistant Staphylococcus aureus. Curr. Clin. Top. Infect. Dis. 8 (1987) 169-180
142. Rahman M. Alternatives to vancomycin in treating methicillin-resistant Staphylococcus aureus infections. J. Antimicrob. Chemother. 41 (1998) 325-328
143. Malik Z., Ladan H., and Nitzan Y. Photodynamic inactivation of Gram-negative bacteria: problems and possible solutions. J. Photochem. Photobiol. B 14 (1992) 262-266
144. Soukos N.S., Ximenez-Fyvie L.A., Hamblin M.R., Socransky S.S., and Hasan T. Targeted antimicrobial photochemotherapy. Antimicrob. Agents Chemother. 42 (1998) 2595-2601
145. abstract 392. Hamblin M.R., O'Donnell D.A., Murthy N., Rajagopalan K., Sherwood M.E., and Hasan T. Photoinactivation of antibiotic-resistant bacteria using polycationic photosensitizer conjugates. Proceedings of the 13th International Congress on Photobiology. San Francisco, CA (2000) 131
146. abstract O99. Hamblin M.R., Soukos N.S., and Hasan T. Selective photoinactivation of gram. positive and gram. negative bacteria while sparing mammalian cells. Proceedings of the 7th Congress of the European Society for Photobiology. Stresa, Italy (1997) 79
147. abstract 393. Hamblin M.R., O'Donnell D.A., Murthy N., Contag C.H., McManus A.T., and Hasan T. Photodynamic inactivation of luminescent bacteria in contaminated and infected wounds in the mouse. Proceedings of the 13th International Congress on Photobiology. San Francisco, CA (2000) 131
148. Hamblin M.R., O'Donnell D.A., Murthy N., Rizvi I., and Hasan T. Targeted photoinactivation of gram. negative bacterial contamination in wounds. Proceedings of the 8th Congress of the European Society for Photobiology. Granada, Spain (1999)
149. Contag C.H., Contag P.R., Mullins J.I., Spilman S.D., Stevenson D.K., and Benaron D.A. Photonic detection of bacterial pathogens in living hosts. Mol. Microbiol. 18 (1995) 593-603
150. Zoladek T., Nguyen B.N., Jagiello I., Graczyk A., and Rytka J. Diamino acid derivatives of porphyrins penetrate into yeast cells, induce photodamage, but have no mutagenic effect. Photochem. Photobiol. 66 (1997) 253-259
151. Paardekooper M., De Bruijne A.W., Van Steveninck J., and Van den Broek P.J. Intracellular damage in yeast cells caused by photodynamic treatment with toluidine blue. Photochem. Photobiol. 61 (1995) 84-89
152. Carre V., Gaud O., Sylvain I., Bourdon O., Spiro M., Blais J., Granet R., Krausz P., and Guilloton M. Fungicidal properties of meso-arylglycosylporphyrins: influence of sugar substituents on photoinduced damage in the yeast Saccharomyces cerevisiae. J. Photochem. Photobiol. B 48 (1999) 57-62
153. Odds F.C. Pathogenesis of Candida infections. J. Am. Acad. Dermatol. 31 (1994) S2-S5
154. Rupke S.J. Fungal skin disorders. Prim. Care 27 (2000) 407-421
155. Bouquot J.E., and Fenton S.J. Juvenile juxtavermilion candidiasis: yet another form of an old disease?. J. Am. Dent. Assoc. 116 (1988) 187-192
156. Kamarashev J.A., and Vassileva S.G. Dermatologic diseases of the vulva. Clin. Dermatol. 15 (1997) 53-65
157. Berger T.G. Treatment of bacterial, fungal, and parasitic infections in the HIV-infected host. Semin. Dermatol. 12 (1993) 296-300
158. Wilson M., and Dobson J. Lethal photosensitization of oral anaerobic bacteria. Clin. Infect. Dis. 16 Suppl. 4 (1993) S414-S415
159. Wilson M. Susceptibility of oral bacterial biofilms to antimicrobial agents. J. Med. Microbiol. 44 (1996) 79-87
160. Wilson M., Dobson J., and Sarkar S. Sensitization of periodontopathogenic bacteria to killing by light from a low-power laser. Oral Microbiol. Immunol. 8 (1993) 182-187
161. Listgarten M.A. The structure of dental plaque. Periodontol. 5 (2000) 52-65
162. Listgarten M.A. Pathogenesis of periodontitis. J. Clin. Periodontol. 13 (1986) 418-430
163. Chen H.Y., Cox S.W., Eley B.M., Mantyla P., Ronka H., and Sorsa T. Matrix metalloproteinase-8 levels and elastase activities in gingival crevicular fluid from chronic adult periodontitis patients. J. Clin. Periodontol. 27 (2000) 366-369
164. Liebana J., and Castillo A. Physiopathology of primary periodontitis associated with plaque. Microbial and host factors. A review. Part 1. Aust. Dent. J. 39 (1994) 228-232
165. Potempa J., and Travis J. Porphyromonas gingivalis proteinases in periodontitis, a review. Acta. Biochim. Pol. 43 (1996) 455-465
166. Vyas S.P., Sihorkar V., and Mishra V. Controlled and targeted drug delivery strategies towards intraperiodontal pocket diseases. J. Clin. Pharm. Ther. 25 (2000) 21-42